Fibrobiologics (Nasdaq: Fblg) company information, Employees & Contact Information

FibroBiologics to Present at Bio-Europe 2025 GlobeNewswire

FibroBiologics to Present at Bio-Europe 2025 Conference in Vienna Quiver Quantitative

FibroBiologics (NASDAQ: FBLG) to present at Bio-Europe 2025; investor meetings in Vienna Stock Titan

FibroBiologics Announces Positive IND-Enabling Updates Demonstrating Potential of Fibroblast Spheroids in Chronic-Relapse Psoriasis Treatment Yahoo Finance

FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies Yahoo Finance

FibroBiologics, Inc. Chief Scientific Officer to Present Innovations at 2025 Cell & Gene Meeting on the Mesa Quiver Quantitative

270+ Patents: Biotech FibroBiologics to Showcase Fibroblast Therapy Pipeline at Major Cell & Gene Conference Stock Titan

FibroBiologics Confirms Ability to Manufacture CybroCell™ for Degenerative Disc Disease and Cartilage Repair Programs from Existing CYWC628 Master Cell Bank Yahoo Finance

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer Yahoo Finance

FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa GlobeNewswire

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire

FibroBiologics Announces Significant Advancements in Bone GlobeNewswire

FibroBiologics Publishes Opinion Editorial Advocating for Superiority of Fibroblast Cells Over Stem Cell Therapies Quiver Quantitative

275+ Patent Biotech Leader FibroBiologics to Showcase Fibroblast Therapies at Major Investment Conference Stock Titan

FibroBiologics Reports First Quarter 2025 Financial Results and Provides Corporate Update Yahoo Finance

Breakthrough in Chronic Disease Treatment: FibroBiologics' 270+ Patents Show Fibroblasts Beat Stem Cells Stock Titan

Single-Dose Treatment Matches Multiple Antibody Doses: FibroBiologics' Breakthrough in Psoriasis Therapy Stock Titan

FibroBiologics to Present Company Update and Research Advances at BIO International Convention 2025 Nasdaq

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing GlobeNewswire

FibroBiologics, Inc. Announces Investor Webinar on Innovative Fibroblast-Based Cell Therapy Platform Nasdaq

FibroBiologics Raises $5M, Fast-Tracks Revolutionary Fibroblast Therapy for Diabetic Foot Ulcers Stock Titan

FibroBiologics Unveils New and Expanded Houston Laboratory GlobeNewswire

FibroBiologics to Reveal Next-Gen Cell Therapy Platform: 275+ Patents Target Billion-Dollar Markets Stock Titan

Houston regenerative medicine company expands lab for future trials InnovationMap

Houston founder on shaping the future of medicine through biotechnology and resilience InnovationMap

FibroBiologics Reveals Breakthrough Diabetic Foot Ulcer Treatment Ahead of Phase 1/2 Trial Stock Titan

Breakthrough: FibroBiologics Achieves Major Cost-Saving Milestone in Degenerative Disc Disease Treatment Development Stock Titan

BioVie and FibroBiologics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV Worcester Telegram

FibroBiologics Taps Former Virax IPO Leader as CFO Ahead of Critical Clinical Trials Stock Titan

FibroBiologics Research Scientist Presents Innovative Thymus Organoid Development at ThymUS 2025 Meeting Quiver Quantitative

FibroBiologics, Inc. Announces $25 Million Standby Equity Purchase Agreement with Yorkville Advisors Quiver Quantitative

FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG PR Newswire

FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology Stock Titan

FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference Stock Titan

FibroBiologics Dedicates Laboratory Facility as the Newlin-Linscomb Lab for Cell Therapeutics PR Newswire

3 Houston innovators to know this week InnovationMap

FibroBiologics Secures $100 Million Capital Commitment from GEM as Company Seeks to Go Public PR Newswire

Houston health care company raises $100M and plans to IPO InnovationMap